Cancer specialists diagnose and develop treatment plans for all types of sarcomas using the latest tests and procedures at the Abramson Cancer Center.
The sarcoma program at Penn Medicine’s Abramson Cancer Center combines the expertise of different doctors, nurses and other health care professionals. Our interdisciplinary team approach means that experts in treatment, nutrition, support and other areas will assist you in developing a total body approach for your cancer treatment. Our sarcoma program includes treatment for:
We are one of ten cancer centers in the U.S. who are members of the Sarcoma Alliance for Collaboration through Research (SARC). Our program includes doctors from all the fields necessary to properly treat and diagnose all types of sarcomas, including specialists in:
What Causes Sarcoma?
Scientists do not yet fully understand what causes sarcomas. Some studies suggest that workers who are exposed to phenoxyacetic acid in herbicides and chlorophenols in wood preservatives may have an increased risk of developing soft tissue sarcomas.
An unusual percentage of patients with a rare blood vessel tumor of the liver called angiosarcoma have been exposed to vinyl chloride in their work. This substance is used in the manufacture of certain plastics.
Recent studies have focused on genetic mutations (changes in the DNA) that may lead to the development of sarcomas. Scientists have found a small number of families in which more than one member of the family has developed sarcoma. In these families, it is possible that sarcoma is related to a rare inherited genetic mutation.
Our Sarcoma Risk Assessment Program provides education about the benefits, limitations, and potential drawbacks of genetic testing. Certain inherited diseases are associated with an increased risk of developing bone and soft tissue sarcomas. Those at increased risk include:
- Individuals with Li-Fraumeni syndrome, which is associated with alterations in the p53 gene.
- Individuals with von Recklinghausen's disease, also called neurofibromatosis, and associated with alterations in the NF1 gene.
- Individuals with Paget's disease, a non-cancerous condition characterized by abnormal development of new bone cells.
- Individuals with hereditary retinoblastoma, which is an uncommon cancer of the eye, that typically develops in childhood.
Your doctor or nurse may ask you if you are interested in participating in current genetic research focused on improving treatment, finding the cause and hopefully preventing sarcomas. We encourage you to ask questions so you'll have the information you need to make the decision that's best for you.
Oncology Patient Navigators
Every step of cancer treatment, from diagnosis, to surgery and treatment, to forming a survivorship plan, comes with different needs and issues that should be addressed.
Oncology patient navigators are committed to making sure every patient’s experience is as comfortable as possible. They are experts in navigating complex health care situations and serve as a consistent point of contact and a reliable source for advice, support and direction for patients and families.